Richard Rupp

View Scopus Profile

Emailrrupputmbedu

h-index

Research activity per year

If you made any changes in Pure these will be visible here soon.

Research Strategic Pillar Keywords

Life Span Health

Fingerprint

Dive into the research topics where Richard Rupp is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

32 Active
164 Completed

Phase 2 Clinical Trial to Optimize Immune Coverage of SARS-CoV-2 Existing and Emerging Variants (short title, COVID-19 Adaptive Variant Immunologic Landscape Trial (COVAIL Trial)
Rupp, R.
3/31/22 → 12/31/23
Project: Other project
A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
Rupp, R.
2/14/22 → 2/13/27
Project: Other project
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
Rupp, R.
2/11/22 → 2/10/27
Project: Other project
A Phase 1/2, First-Time-in Human (FTiH), randomized, observer-blind, placebo-controlled, dose escalation study to assess safety, reactogenicity and immunogenicity of a candidate cytomegalovirus (CMV) vaccine comprising recombinant protein and adjuvant wh
Rupp, R.
11/12/21 → 11/11/26
Project: Other project
PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTH
Rupp, R.
3/29/21 → 3/28/26
Project: Other project

50 Article
6 Review article
2 Chapter
1 Editorial
More
- 1 Letter

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)
for the V114-029 PNEU-PED study group, Jan 27 2023, In: Vaccine. 41, 5, p. 1142-1152 11 p.
Research output: Contribution to journal › Article › peer-review

Open Access
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults
Russell, K. L., Rupp, R. E., Morales-Ramirez, J. O., Diaz-Perez, C., Andrews, C. P., Lee, A. W., Finn, T. S., Cox, K. S., Falk Russell, A., Schaller, M. M., Martin, J. C., Hyatt, D. M., Gozlan-Kelner, S., Bili, A. & Coller, B. A. G., 2022, In: Human Vaccines and Immunotherapeutics. 18, 5, 2046960.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations
Homologous and Heterologous Covid-19 Booster Vaccinations
Atmar, R. L., Lyke, K. E., Deming, M. E., Jackson, L. A., Branche, A. R., El Sahly, H. M., Rostad, C. A., Martin, J. M., Johnston, C., Rupp, R. E., Mulligan, M. J., Brady, R. C., Frenck, R. W., Bäcker, M., Kottkamp, A. C., Babu, T. M., Rajakumar, K., Edupuganti, S., Dobrzynski, D., Coler, R. N., & 18 othersPosavad, C. M., Archer, J. I., Crandon, S., Nayak, S. U., Szydlo, D., Zemanek, J. A., Dominguez Islas, C. P., Brown, E. R., Suthar, M. S., McElrath, M. J., McDermott, A. B., O’Connell, S. E., Montefiori, D. C., Eaton, A., Neuzil, K. M., Stephens, D. S., Roberts, P. C. & Beigel, J. H., Mar 17 2022, In: New England Journal of Medicine. 386, 11, p. 1046-1057 12 p.
Research output: Contribution to journal › Article › peer-review
168 Scopus citations
Human papillomavirus dose reminder preferences among parents from a diverse clinical sample: a qualitative study
Hirth, J., Eboreime, K. A., Cofie, L., Rupp, R. E. & Berenson, A. B., 2022, In: Human Vaccines and Immunotherapeutics. 18, 1, 2031697.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
Coronavirus Efficacy (COVE) Study Group, Nov 11 2022, In: The Journal of infectious diseases. 226, 10, p. 1731-1742 12 p.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations

Richard Rupp, MD

Personal profile

Research Strategic Pillar Keywords

Fingerprint

Network

Dive into details

Phase 2 Clinical Trial to Optimize Immune Coverage of SARS-CoV-2 Existing and Emerging Variants (short title, COVID-19 Adaptive Variant Immunologic Landscape Trial (COVAIL Trial)

A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

A Phase 1/2, First-Time-in Human (FTiH), randomized, observer-blind, placebo-controlled, dose escalation study to assess safety, reactogenicity and immunogenicity of a candidate cytomegalovirus (CMV) vaccine comprising recombinant protein and adjuvant wh

PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTH

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)

A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults

Homologous and Heterologous Covid-19 Booster Vaccinations

Human papillomavirus dose reminder preferences among parents from a diverse clinical sample: a qualitative study

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial

Richard Rupp, MD

Personal profile

Research Strategic Pillar Keywords

Fingerprint

Network

Projects

Research output